Shunli Q. Shen
58 Zhongshan 2nd Road
Guangzhou, 510080, China
Guangzhou, 510080, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications
Retraction Note: Nanomedicines reveal how PBOV1 promotes hepatocellular carcinoma for effective gene therapy.
Journal: Nature communications
Published: December 16, 2025
Targeting m6A Reader YTHDF1 Enhances Antitumor Immunity and Potentiates Anti-PD-L1 Efficacy in Intrahepatic Cholangiocarcinoma.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 16, 2025
Pathological Complete Response after Systemic Therapy and Curative Resection in Initially Unresectable Hepatocellular Carcinoma: Feasibility of a Tumor-Free with Drug-Free Strategy.
Journal: Liver cancer
Published: August 06, 2025
Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 10, 2025
METTL1-Mediated M7G tRNA Modification Promotes Residual Liver Regeneration After Hepatectomy via Translational Control.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 23, 2025
Erratum: Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
Journal: Hepatology (Baltimore, Md.)
Published: March 27, 2025
Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).
Journal: Hepatobiliary surgery and nutrition
Published: February 28, 2025
Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice.
Journal: Hepatology (Baltimore, Md.)
Published: January 12, 2025
Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).
Journal: Bioscience trends
Published: December 25, 2024
Conversion Therapy Based on TACE/HAIC-Based Treatment to Improve the Therapeutic Effect of Initially Unresectable Hepatocellular Carcinoma.
Journal: Liver cancer
Published: November 21, 2024
Last Updated: 09/26/2026